HC Wainwright & Co. Reiterates Veru (VERU) Buy Recommendation

Fintel reports that on September 27, 2023, HC Wainwright & Co. reiterated coverage of Veru (NASDAQ:VERU) with a Buy recommendation.

Analyst Price Forecast Suggests 325.00% Upside

As of August 31, 2023, the average one-year price target for Veru is 3.40. The forecasts range from a low of 1.01 to a high of $7.35. The average price target represents an increase of 325.00% from its latest reported closing price of 0.80.

See our leaderboard of companies with the largest price target upside.

The projected annual revenue for Veru is 40MM, an increase of 168.31%. The projected annual non-GAAP EPS is -1.34.

What is the Fund Sentiment?

There are 142 funds or institutions reporting positions in Veru. This is a decrease of 84 owner(s) or 37.17% in the last quarter. Average portfolio weight of all funds dedicated to VERU is 0.00%, a decrease of 47.53%. Total shares owned by institutions decreased in the last three months by 47.87% to 17,376K shares. The put/call ratio of VERU is 0.27, indicating a bullish outlook.

What are Other Shareholders Doing?

VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 1,924K shares representing 2.13% ownership of the company. No change in the last quarter.

Millennium Management holds 978K shares representing 1.08% ownership of the company. In it's prior filing, the firm reported owning 0K shares, representing an increase of 100.00%.

VCSAX - Vanguard Consumer Staples Index Fund Admiral Shares holds 820K shares representing 0.91% ownership of the company. In it's prior filing, the firm reported owning 820K shares, representing a decrease of 0.02%. The firm decreased its portfolio allocation in VERU by 75.54% over the last quarter.

Norges Bank holds 801K shares representing 0.89% ownership of the company. In it's prior filing, the firm reported owning 0K shares, representing an increase of 100.00%.

VEXMX - Vanguard Extended Market Index Fund Investor Shares holds 745K shares representing 0.83% ownership of the company. No change in the last quarter.

Veru Background Information
(This description is provided by the company.)

Veru Inc. is an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer and breast cancer. The Veru prostate cancer pipeline includes VERU-111, VERU-100, and Zuclomiphene citrate. VERU-111 is an oral, first-in-class, new chemical entity that targets, crosslinks, and disrupts alpha and beta tubulin subunits of microtubules for the treatment of metastatic castration and androgen receptor resistant prostate cancer. VERU-100 is a novel, proprietary peptide formulation designed to address the current limitations of commercially available androgen deprivation therapies (ADT) for advanced prostate cancer. Zuclomiphene citrate is an oral nonsteroidal estrogen receptor agonist being developed to treat hot flashes, a common side effect caused by ADT in men with advanced prostate cancer. The Veru breast cancer pipeline includes enobosarm for AR+/ER+/HER2- metastatic breast cancer and VERU-111 for taxane resistant metastatic triple negative breast cancer. Enobosarm is an oral, first-in-class, new chemical entity, selective androgen receptor agonist that targets and activates the androgen receptor in AR+/ER+/HER2- metastatic breast cancer without unwanted masculinizing side effects. VERU-111 is also being advanced into a Phase 3 trial for the treatment of hospitalized patients with COVID-19 who are at high risk for acute respiratory distress syndrome.

Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.

Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.

Click to Learn More

This story originally appeared on Fintel.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.